Falk Symposium 183
Basel, May 4–5, 2012

Dealing with Our ‘In-Vironment’: New Aspects in IBD Pathogenesis and Therapy

Editors
G. Rogler, Zurich
C. Beglinger, Basel
J.-F. Colombel, Lille
P. Michetti, Lausanne

28 figures and 22 tables, 2012
Contents

Introduction

1 Dealing with Our ‘In-Vironment’: New Aspects of Inflammatory Bowel Disease Pathogenesis and Therapy
   Rogler, G. (Zürich)

Genetic Risk Factors in IBD: Impaired Control of the ‘In-Vironment’?

2 Genes and ‘In-Vironment’: How Will Our Concepts on the Pathophysiology of Inflammatory Bowel Disease Develop in the Future?
   Fiocchi, C. (Cleveland, Ohio)

IBD: The ‘In-Vironment’ out of Control?

12 Inflammatory Bowel Disease: Dysfunction of Autophagy?
   Scharl, M.; Rogler, G. (Zurich)

20 Environmental Factors and Their Impact on the Intestinal Microbiota: A Role for Human Disease?
   Biedermann, L.; Rogler, G. (Zurich)

Environment and ‘In-Vironment’

28 Why and Where to Look in the Environment with Regard to the Etiology of Inflammatory Bowel Disease
   Bernstein, C.N. (Winnipeg, Man.)

33 Does Our Food (Environment) Change Our Gut Microbiome (‘In-Vironment’): A Potential Role for Inflammatory Bowel Disease?
   de Wouters, T.; Doré, J.; Lepage, P. (Jouy-en-Josas)

40 Danger-Associated Molecular Patterns and Inflammatory Bowel Disease: Is There a Connection?
   Mueller, C. (Bern)

47 Microparticles and Their Impact on Intestinal Immunity
   Becker, H.M. (Calgary, Alta.); Bertschinger, M.M.; Rogler, G. (Zurich)

Treatment Decisions Made Easy: Do We Have the Disease Markers We Need?

55 Circulating Antibodies against Bacterial Wall Products: Are There Arguments for Early Immunosuppression?
   Rieder, F. (Cleveland, Ohio); Kugathasan, S. (Atlanta, Ga.)

67 Clinical Risk Factors for Complicated Disease: How Reliable Are They?
   Zallot, C.; Peyrin-Biroulet, L. (Vandœuvre-lès-Nancy)

73 Intestinal Absorption and Vitamin Levels: Is a New Focus Needed?
   Vavricka, S.R.; Rogler, G. (Zurich)
Contents

Changing the ‘In-Vironment’ for Therapy

81 Specific Probiotics or ‘Fecal Transplantation’
Kruis, W. (Cologne)

85 Mucosal Protection by Phosphatidylcholine

92 Topical Therapy
Gross, V. (Amberg)

100 The Risks and Benefits of Early Immunosuppression and Biological Therapy
Sands, B.E. (New York, N.Y.)

The Classical Immunosuppression: Overrated or Underused?

107 Deep Remission: A New Concept?
Colombel, J.-F. (Lille); Louis, E. (Liège); Peyrin-Biroulet, L. (Vandoeuvre-lès-Nancy); Sandborn, W.J. (La Jolla, Calif.); Panaccione, R. (Calgary, Alta.)

112 Methotrexate: Underused and Ignored?

119 Extended Abstract: Tacrolimus and Cyclosporine in Inflammatory Bowel Disease
Stange, E.F. (Stuttgart)

Biologics and Beyond

121 Biological Treatment of Crohn’s Disease
Nielsen, O.H.; Bjerrum, J.T.; Seidelin, J.B.; Nyberg, C.; Ainsworth, M. (Copenhagen)

134 Stem Cells as Treatment in Inflammatory Bowel Disease
Hawkey, C.J. (Nottingham)

140 The Future of Inflammatory Bowel Disease Therapy: Where Do We Go from Here?
Sandborn, W.J. (La Jolla, Calif.)

145 Author Index
146 Subject Index